leisure time -WSS

leisure time

author：comprehensive 2025-09-06 01:58:29 - browse：8

Transparent plastic divider on the reception desk in the hospital admission department with red lettering emergency. — Adobe

QuidelOrtho has recalled nearly 8,000 potentially faulty blood tests meant to help doctors quickly determine whether a patient is having a heart attack.

The tests inaccurately showed low levels of troponin, a protein that indicates damage to the heart. A false negative could lead doctors to mistakenly conclude their patient is not having a heart attack, delaying diagnosis or treatment when time is of the essence.

The device maker, which also sells products like the QuickVue Covid-19 antigen test, sent letters to health systems in May telling them to immediately stop using the test. The Food and Drug Administration classified the recall as serious, because problems with the product could result in serious injury or death. QuidelOrtho has reported 41 complaints, but no injuries or deaths so far.

The tests, which use either a blood or plasma sample, promise to return results in under half an hour. They are used in emergency rooms to triage patients suspected of having a heart attack.

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

The FDA said the patients most at risk are those with zero or abnormal heart attack symptoms, for whom a diagnosis would be easy to miss without an accurate lab test.

The company advised using a different testing method to detect heart attacks. If none are available, doctors should be extra wary of the blood panel’s readings, perform multiple tests to confirm low troponin levels, and also reference data from EKGs and other imaging.

San Diego-based QuidelOrtho said the error is due to a “raw material issue” in its recall record. The issue caused the test to falsely pick up 30% less troponin than is present. The company did not respond to STAT’s request for more information on the error.

The test maker’s last serious recall was in 2021 for reports of false negatives from its Lyra PCR Covid-19 test when used with certain lab equipment. The notice impacted more than 18,000 test kits.

Previous article： In Memoriam: Notable people who died in 2023
Next article： Diagnostic tests are hitting their mathematical limits

knowledge

WSS

Bird flu in dairy cattle: New measures to control spread to humans

Organ aging and disease risk measured by new blood test

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

What to do when lifesaving products contribute to climate change

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

hotspot

leisure time

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

focus

Cancer drug shortages should be causing more outrage

Covid silver lining: Unprecedented look at human immune system

Sports medicine is finally prioritizing gender equality

First Opinion on colorectal cancer screening: letter and response

BioMarin wins approval for gene therapy to treat hemophilia A

ReNAgade cuts staff seven months after raising $300 million

Supreme Court strikes down use of affirmative action

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Sports medicine is finally prioritizing gender equality

U.K. decision on ALS drug has neurologists, advocates up in arms

hotspot

First Opinion on colorectal cancer screening: letter and response

ReNAgade cuts staff seven months after raising $300 million

With clinical trial data readouts, here's how to spot spin

Alzheimer's risk factor APOE4 may be a distinct form of the disease

Multiple sclerosis has subtypes with different best treatments: study

Cigna, Humana reportedly in talks to merge

knowledge

leisure time

explore

hotspot